N/A N=13 Hoarding Disorder Treatment With Virtual Reality
Hoarding Disorder · Hoarding · Clutter
Primary: Change in Hoarding Symptom Severity as Measured by Saving Inventory-Revised (SI-R) — 14.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=82 Enhancement of PTSD Treatment With Computerized Executive Function Training
Posttraumatic Stress Disorder
Primary: Wisconsin Card Sorting Test (WCST) — -2.69; -1.47 score on a scale
Phase 2 N=28 Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease)
Sars-CoV2 · Acute Respiratory Distress Syndrome · COVID-19
Primary: Proportion of Participants With Treatment-related Serious Adverse Events (tSAEs) — 0; 0 proportion of participant
N/A N=150 Improving Function in Older Veterans With Hospital-Associated Deconditioning
Frail Elderly · Homebound Persons
Primary: Change in Self-Selected Walking Speed — 0.08; 0.08 m/s
Phase 3 N=22 MK-8228 (Letermovir) in the Prevention of Human Cytomegalovirus (CMV) Infection and Disease in Adult Japanese Kidney Transplant Recipients (MK-8228-042)
Cytomegalovirus Infection · Cytomegalovirus Disease
Primary: Percentage of Participants With Adverse Events (AEs) — 90.9 Percentage of Participants
Phase 1 N=34 Study of Magrolimab (Hu5F9-G4) in Combination With Avelumab in Solid Tumor Participants and Checkpoint-Inhibitor-Naive Ovarian Cancer Participants Who Progress Within 6 Months of Prior Platinum Chemotherapy
Ovarian Cancer
Primary: Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) in Safety Run-in (Part 1) — 0; 0 percentage of participants
N/A N=44 Physiologic Effect of Topical Nitroglycerin on Microcirculation Capacity in Patients With Circulatory Shock.
Circulatory Shock · Cardiovascular Shock
Primary: Perfused Vessel Density (PVD) — 24.81; 20.44; 26.41; 21.88 mm/mm^2
N/A N=47 Boiled Peanut Oral Immunotherapy for the Treatment of Peanut Allergy: a Pilot Study
IgE Mediated Peanut Allergy
Primary: Desensitisation to >1.4g (Roasted) Peanut Protein at Food Challenge — 24; 14 Participants — p=<0.0001
Phase 1 N=24 PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants
Healthy Participants
Primary: Plasma Dabigatran (Total) PK Parameters (PF-07321332/Ritonavir Co-administered With Dabigatran [Treatment 2]): Maximum Plasma Concentration (Cmax) — 71.87; 154.1 ng/mL
N/A N=12 Psychosocial Intervention for Older HIV+ Adults With HAND
HIV/AIDS · Aging · Mild Cognitive Impairment
Primary: Feasibility - Session Attendance — 5; 5 Participants
Phase 2 N=31 Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures
Epilepsy, Partial
Primary: Percentage Change From Baseline in Seizure Frequency Per Week of Partial Onset Seizures (Type I) During the Up-titration Period — -30.88 percentage of change
Phase 1 N=6 A Study To Evaluate The Pharmacokinetics, Excretion, Mass Balance and Metabolism of PF-07265803
Healthy
Primary: Total Recovery of Radioactivity in Urine, Expressed as Percentage of Total Radioactive Dose Administered — 13.98 Percentage of total radioactive dose
N/A N=1,868 Follow up of LEAP Participants and Their Families
Peanut Allergy
Primary: Percentage of LEAP Participants With Peanut Allergy — 15.4; 4.4; 84.6; 95.6 Percentage of Participants — p=<0.001
Phase 1 N=27 A Study to Determine the Bioavailability of Vonoprazan Sprinkle Capsules on Pudding or on Applesauce Relative to a Vonoprazan Tablet in Healthy Participants
Healthy Volunteers
Primary: Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Last Quantifiable Concentration (AUC0-t) of Vonoprazan — 228; 216; 219 ng•h/mL
Phase 1 N=32 Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
Inflammatory Diseases
Primary: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa — 26.9; 41.6; 48.1; 56.1 ng/mL